# Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)

> **NCT02494583** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 763 (actual)

## Conditions studied

- Gastric Adenocarcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Cisplatin
- **DRUG:** 5-FU
- **DRUG:** Capecitabine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02494583
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-31
- **Primary completion:** 2019-03-26
- **Final completion:** 2022-06-06
- **Target enrollment:** 763 (ACTUAL)
- **Last updated:** 2023-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02494583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02494583, "Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02494583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*